Trial · NCT01049009
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
NCT01049009, Phase 4, Completed, Emory University; results first posted 2014-12-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension. Trials, record NCT01049009. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01049009
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
- NCT number
- NCT01049009
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 91 participants, actual
- Lead sponsor
- Emory University
- Conditions
- High Blood Pressure
- Interventions
- Nebivolol, Metoprolol XL
- First posted
- 2010-01-14
- Last updated
- 2017-04-11
- Results first posted
- 2014-12-19
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | 12 weeks | Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute. |
| Primary | Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks | 24 weeks | Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | 12 weeks | mL/100 mL/min | MEAN | |
| PRIMARY | Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks | 24 weeks | mL/100 mL/min | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Nebivolol/Metoprolol XL | At rest | 2.739 | Standard Deviation 1.365 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Metoprolol XL/Nebivolol | At rest | 2.679 | Standard Deviation .0901 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Nebivolol/Metoprolol XL | L-NMMA+TEA | 1.963 | Standard Deviation 0.968 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Metoprolol XL/Nebivolol | L-NMMA+TEA | 2.221 | Standard Deviation 0.630 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Nebivolol/Metoprolol XL | L-NMMA+TEA+ACh | 5.376 | Standard Deviation 3.362 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Metoprolol XL/Nebivolol | L-NMMA+TEA+ACh | 7.562 | Standard Deviation 4.358 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Nebivolol/Metoprolol XL | L-NMMA+TEA+exercise | 7.377 | Standard Deviation 2.754 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks | Metoprolol XL/Nebivolol | L-NMMA+TEA+exercise | 11.574 | Standard Deviation 4.716 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks | Nebivolol/Metoprolol XL | At rest | 3.066 | Standard Deviation 1.469 | mL/100 mL/min |
| Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks | Metoprolol XL/Nebivolol | At rest | 2.968 | Standard Deviation 1.164 | mL/100 mL/min |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period 1 (12 Weeks) | STARTED | Nebivolol/Metoprolol XL | 23 | |
| Treatment Period 1 (12 Weeks) | STARTED | Metoprolol XL/Nebivolol | 21 | |
| Treatment Period 1 (12 Weeks) | COMPLETED | Nebivolol/Metoprolol XL | 21 | |
| Treatment Period 1 (12 Weeks) | COMPLETED | Metoprolol XL/Nebivolol | 18 | |
| Treatment Period 1 (12 Weeks) | NOT COMPLETED | Nebivolol/Metoprolol XL | 2 | |
| Treatment Period 1 (12 Weeks) | NOT COMPLETED | Metoprolol XL/Nebivolol | 3 | |
| Treatment Period 2 (12 Weeks) | STARTED | Nebivolol/Metoprolol XL | 21 | |
| Treatment Period 2 (12 Weeks) | STARTED | Metoprolol XL/Nebivolol | 18 | |
| Treatment Period 2 (12 Weeks) | COMPLETED | Nebivolol/Metoprolol XL | 11 | |
| Treatment Period 2 (12 Weeks) | COMPLETED | Metoprolol XL/Nebivolol | 8 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Nebivolol/Metoprolol XL | ||
| Total, all-cause mortality | Metoprolol XL/Nebivolol | ||
| Total, other adverse events | Nebivolol/Metoprolol XL | 0 | 23 |
| Total, other adverse events | Metoprolol XL/Nebivolol | 0 | 21 |
| Total, serious adverse events | Nebivolol/Metoprolol XL | 0 | 23 |
| Total, serious adverse events | Metoprolol XL/Nebivolol | 0 | 21 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26285691 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Nebivolol/Metoprolol XL vs Metoprolol XL/Nebivolol: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01049009
GET https://conductscience.org/api/trials/v1/NCT01049009/registered